Show simple item record

dc.contributor.authorScott, AJ
dc.contributor.authorAlexander, JL
dc.contributor.authorMerrifield, CA
dc.contributor.authorCunningham, D
dc.contributor.authorJobin, C
dc.contributor.authorBrown, R
dc.contributor.authorAlverdy, J
dc.contributor.authorO'Keefe, SJ
dc.contributor.authorGaskins, HR
dc.contributor.authorTeare, J
dc.contributor.authorYu, J
dc.contributor.authorHughes, DJ
dc.contributor.authorVerstraelen, H
dc.contributor.authorBurton, J
dc.contributor.authorO'Toole, PW
dc.contributor.authorRosenberg, DW
dc.contributor.authorMarchesi, JR
dc.contributor.authorKinross, JM
dc.date.accessioned2020-06-03T10:06:29Z
dc.date.issued2019-09-01
dc.identifier.citationGut, 2019, 68 (9), pp. 1624 - 1632
dc.identifier.issn0017-5749
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3676
dc.identifier.eissn1468-3288
dc.identifier.doi10.1136/gutjnl-2019-318556
dc.description.abstractOBJECTIVE: In this consensus statement, an international panel of experts deliver their opinions on key questions regarding the contribution of the human microbiome to carcinogenesis. DESIGN: International experts in oncology and/or microbiome research were approached by personal communication to form a panel. A structured, iterative, methodology based around a 1-day roundtable discussion was employed to derive expert consensus on key questions in microbiome-oncology research. RESULTS: Some 18 experts convened for the roundtable discussion and five key questions were identified regarding: (1) the relevance of dysbiosis/an altered gut microbiome to carcinogenesis; (2) potential mechanisms of microbiota-induced carcinogenesis; (3) conceptual frameworks describing how the human microbiome may drive carcinogenesis; (4) causation versus association; and (5) future directions for research in the field.The panel considered that, despite mechanistic and supporting evidence from animal and human studies, there is currently no direct evidence that the human commensal microbiome is a key determinant in the aetiopathogenesis of cancer. The panel cited the lack of large longitudinal, cohort studies as a principal deciding factor and agreed that this should be a future research priority. However, while acknowledging gaps in the evidence, expert opinion was that the microbiome, alongside environmental factors and an epigenetically/genetically vulnerable host, represents one apex of a tripartite, multidirectional interactome that drives carcinogenesis. CONCLUSION: Data from longitudinal cohort studies are needed to confirm the role of the human microbiome as a key driver in the aetiopathogenesis of cancer.
dc.formatPrint-Electronic
dc.format.extent1624 - 1632
dc.languageeng
dc.language.isoeng
dc.publisherBMJ PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectColorectal Neoplasms
dc.subjectDNA Damage
dc.subjectInflammation
dc.subjectBiomedical Research
dc.subjectMicrobiota
dc.subjectCarcinogenesis
dc.subjectDysbiosis
dc.subjectGastrointestinal Microbiome
dc.titleInternational Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis.
dc.typeJournal Article
dcterms.dateAccepted2019-04-24
rioxxterms.versionofrecord10.1136/gutjnl-2019-318556
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2019-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfGut
pubs.issue9
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Medicine (Brown Epigenetic Therapy)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume68
pubs.embargo.termsNot known
icr.researchteamMedicine (RMH Smith Cunningham)
icr.researchteamMedicine (Brown Epigenetic Therapy)
dc.contributor.icrauthorBrown, Robert


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0